688131 Shanghai Haoyuan Chemexpress
- 33.13
- -0.23-0.69%
Shanghai Haoyuan Chemexpress News
Haoyuan Pharmaceutical (688131.SH)'s net profit for the first quarter of 167.574 million yuan decreased by 63.76% year-on-year
Gelonghui, April 29丨Haoyuan Pharmaceutical (688131.SH) released its report for the first quarter of 2024. Operating revenue during the reporting period was 505 million yuan, up 20.68% year on year; net profit attributable to shareholders of listed companies was 16.7574 million yuan, a year-on-year decrease of 63.76%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 13.922,300 yuan, a year-on-year decrease of 66.82%, with basic earnings per share of 0.11 yuan.
Haoyuan Pharmaceutical (688131): Industry competition affects gross margin capacity building continues to advance
Matters: The company released its 2023 annual report and achieved full-year revenue of 1,888 billion yuan (+38.44%), realized net profit of 127 million yuan (-34.18%), and net profit after deduction of 110 million yuan (-29)
Haoyuan Pharmaceutical (688131.SH) announced its 2023 annual results, with net profit of 127 million yuan, a year-on-year decrease of 34.18%
According to the Zhitong Finance App, Haoyuan Pharmaceutical (688131.SH) disclosed its 2023 annual report. The company achieved revenue of 1.88 billion yuan in 2023, an increase of 38.44%; net profit to mother was 127 million yuan, a year-on-year decrease of 34.18%; deducted non-net profit of 110 million yuan, a year-on-year decrease of 29.58%; and basic earnings per share were 0.85 yuan. The company plans to pay a cash dividend of 1.50 yuan (tax included) for every 10 shares, adding 4 shares for every 10 shares.
The A-share diet pill concept fluctuated higher. Kanghui Pharmaceutical went up and down, Kangpeng Technology rose more than 6%, and Nanowei Technology, Haoyuan Pharmaceutical, Medici, and Prius followed suit.
The A-share diet pill concept fluctuated higher. Kanghui Pharmaceutical went up and down, Kangpeng Technology rose more than 6%, and Nanowei Technology, Haoyuan Pharmaceutical, Medici, and Prius followed suit.
CRO concept stocks surged higher in the afternoon. Zhaoyan Pharmaceutical rose more than 8%, Tiger Pharmaceuticals rose more than 7%, and Norske, Haoyuan Pharmaceuticals, and Pharmaceutical Stone Technology rose more than 4%.
CRO concept stocks surged higher in the afternoon. Zhaoyan Pharmaceutical rose more than 8%, Tiger Pharmaceuticals rose more than 7%, and Norske, Haoyuan Pharmaceuticals, and Pharmaceutical Stone Technology rose more than 4%.
The concept of diet pills fluctuated and declined, with Aimeike falling more than 7%, Huadong Pharmaceutical and Zhengguang shares falling by more than 4%, and Haoyuan Pharmaceuticals, Medici, and Shengnuo Biotech.
The concept of diet pills fluctuated and declined, with Aimeike falling more than 7%, Huadong Pharmaceutical and Zhengguang shares falling by more than 4%, and Haoyuan Pharmaceuticals, Medici, and Shengnuo Biotech.
Haoyuan Chemexpress to Issue 822 Million Yuan Worth of Convertible Bonds
Shanghai Haoyuan Chemexpress (SHA:688131) proposed to issue convertible corporate bonds worth up to 822.4 million yuan, the company said in its filing on the Shanghai Stock Exchange. The proceeds from
Haoyuan Chemexpress to Raise Subsidiary's Capital by 200 Million Yuan
Shanghai Haoyuan Chemexpress (SHA:688131) plans to raise the capital of subsidiary Anhui Haoyuan Pharmaceutical by 200 million yuan through debt-for-equity swaps, the company said in the filing on the
Haoyuan Pharmaceutical (688131.SH): Capital increase of 200 million yuan for wholly-owned subsidiary through debt-to-equity swaps
Gelonghui, March 22丨Haoyuan Pharmaceutical (688131.SH) announced that on March 22, 2024, the company held the 34th meeting of the 3rd board of directors and the 32nd meeting of the 3rd board of supervisors to review and pass the “Proposal on Increasing the Capital of Wholly-owned Subsidiaries by using debt-for-equity swaps”, and agreed that the company would use funds raised to increase the capital of Anhui Haoyuan by RMB 20.00 million. After the capital increase was completed, the registered capital of Anhui Haoyuan increased from RMB 20 million to RMB 40 million. It is a wholly-owned subsidiary of the company.
Haoyuan Pharmaceutical (688131.SH): It has formed strategic cooperation with AI pharmaceutical company Derui Zhi Pharmaceutical and clinical-stage biomedical company Insili Smart
Gelonghui, March 20 | Haoyuan Pharmaceutical (688131.SH) said on the investor interactive platform that artificial intelligence can summarize and extract the molecular rules of compounds through automatic learning based on existing molecular structures and activities, thereby generating many compounds that have never existed in nature as drug candidate molecules, constructing molecular banks with a certain scale and high quality, expanding chemical space, and providing more leading compounds for drug development. At present, the company has formed strategic cooperation with AI pharmaceutical company Deruizhi Pharmaceutical and clinical-stage biomedical company Insili Smart to help new drug development break through technical barriers and promote artificial intelligence through AI models
A-share diet drug concept stocks bottomed out and rebounded
Glonghui, March 18 | Haoyuan Pharmaceutical rose more than 6%, Medici rose more than 5%, and Boji Pharmaceuticals and Shengnuo Biotech followed suit.
Haoyuan Pharmaceutical (688131): Brand and technology drive revenue growth and wait for the industry to warm up
Core view: Front-end categories are being iterated at an accelerated pace, and the brand effect is showing to drive continuous revenue growth. According to the Company Express, in 2023, the company achieved total revenue of 1,889 billion yuan, an increase of 38.36% over the previous year; it returned to the parent company
Haoyuan Pharmaceutical (688131): Rapid revenue growth, multiple factors affect 2023Q4 profit
Incident: The company released the 2023 performance report. In 2023, the company achieved operating income of 1,889 million yuan, an increase of 38.36%; net profit to mother was 121 million yuan, a year-on-year decrease of 37.45%; deducted from non-return to mother
Haoyuan Pharmaceutical (688131.SH) performance report: 2023 net profit of 121 million yuan fell 37.45% year on year
Gelonghui, Feb. 23: Haoyuan Pharmaceutical (688131.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating revenue of 1,889 million yuan, a year-on-year increase of 38.36%; realized net profit attributable to owners of the parent company of 121 million yuan, a year-on-year decrease of 37.45%; and realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 101 million yuan, a year-on-year decrease of 35.44%. At the end of the reporting period, the company's total assets were 4216.1248 million yuan, an increase of 16.18% over the beginning of the reporting period; owners' equity attributable to the parent company was 247,5
Some shareholders of Haoyuan Pharmaceutical (688131.SH) completed a total reduction of 1.61% of their shares
Haoyuan Pharmaceutical (688131.SH) announced that the company's shareholder Shanghai Zhenjin High-tech Service Industry Venture Capital Center (Limited...
Haoyuan Pharmaceutical (688131.SH): Proposed 2024 employee stock ownership plan to raise no more than 75 million yuan
Gelonghui, Feb. 1: Haoyuan Pharmaceutical (688131.SH) announced its 2024 employee stock ownership plan. The total capital raised by the employee stock ownership plan is no more than 75 million yuan. Using “shares” as the subscription unit, each share is 1 yuan, that is, the number of shares in the employee's shareholding plan is no more than 75 million shares. The employee's shareholding plan is to acquire and hold shares through special financial products, and plans to achieve a ratio of no more than 1:1 between financing capital and self-financing through methods permitted by laws and regulations, such as securities financing, etc., that is, the amount of financing from financial institutions does not exceed 75 million yuan.
Haoyuan Pharmaceutical (688131.SH): Bailey Tianheng is a customer Haoyuan Pharmaceutical has cooperated with for many years
Glonghui, December 13|Some investors asked Haoyuan Pharmaceutical (688131.SH) on the investor interactive platform, “Among the company's more than 500 ADC customers, does Bailey Tianheng have?” The company said that Haoyuan Pharmaceutical has been deeply involved in the field of ADC small molecules for more than 10 years. It is one of the earliest domestic companies to carry out ADC payload-linker research. It has an experienced technical team and is committed to providing domestic and foreign customers with end-to-end one-stop solutions for ADC small molecules. Since 2013, Haoyuan Pharmaceutical has developed a series of widely used ADC high-activity payloads (
Haoyuan Pharmaceutical (688131): Revenue remains high and profits are yet to be released
Event description The company released its 2023 three-quarter report. In the third quarter of 2023, the company achieved revenue of 495 million yuan, an increase of 41.95% over the previous year; realized net profit of 23 million yuan, a decrease of 43.79% over the previous year; in fact
Haoyuan Pharmaceutical (688131): Continued release of momentum, optimistic about profit improvement
Key investment views: The growth momentum is clear and continuous, and there is plenty of room for profitability optimization. Optimistic about the inflection point in 2024 profit growth, we have reviewed the company's performance in the first three quarters of 2023. The changing trend in the company's gross margin reflects the domestic CX
Express News | Haoyuan Pharmaceutical: The company's biological reagents are still relatively small compared to other businesses
Analysis
Price Target
No Data
